Takeda specialises in pharmaceutical services and is committed to improve patients’ quality of life. Excerpts from an interview with Danilo Cassani, the Area Head of Near East, Middle East and Africa (NEMEA):
Takeda has been providing better health for a brighter future for patients. Please elaborate.
At Takeda, we are committed to bring better health and a brighter future to patients by translating science into life-changing medicines. Our research and developments efforts are focused on oncology, gastroenterology and central nervous system therapeutic areas, as well as vaccines. We are committed to serve the needs of our patients, wherever they are. We are recognised as best-in-class because of agility and innovation, qualities that help us build a steady pipeline and deliver growth year on year.
Tell us how Takeda goes the extra mile for patients.
Patient-centricity is a key element of Takeda-ism. It is reflected in the way we do business and all our strategies revolve around patients.
One example of this is Takeda’s Patient Assistance Programmes (PAP), which are a cornerstone of our bold, new Access to Medicines strategy. Our PAPs utilise an innovative, collaborative approach to optimise care and treatment benefits. They enable eligible patients to complete their entire course of treatment with some of our speciality medicines, even if they cannot afford to pay for it in full. We aim to introduce such programmes in several countries throughout the region in the coming months
Do you feel there has been a change in the needs of patients in the healthcare sector? How does Takeda cater to it?
Healthcare is different from any other industry because of the high ethical implications —positive and negative — linked to people’s well-being. Patients’ needs have certainly changed over time, which has not only raised the bar for innovation, but also facilitated advanced and effective methods of communication and interaction with patients. At Takeda, we’ve become selective with our investments to maximise impact on patients, and our R&D division is targeted towards specific diseases and treatments. Innovation is crucial to improving patient’s health. It not only encourages new treatments, but also provides patients with access to medicines quickly in a cost-effective manner.
